REGULATORY T-CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA

Regulatory T-cells (Tregs) constitute a small subset of cells that are actively involved in maintaining self-tolerance, in immune homeostasis and in antitumor immunity. They are thought to play a significant role in the progression of cancer and are generally increased in patient with chronic lymph...

Full description

Bibliographic Details
Main Authors: Giovanni D'Arena, Giovanni Rossi, Barbara Vannata, Silvia Deaglio
Format: Article
Language:English
Published: PAGEPress Publications 2014-08-01
Series:Mediterranean Journal of Hematology and Infectious Diseases
Online Access:https://mjhid.org/index.php/mjhid/article/view/1680
id doaj-ab726cf4de894ff0b40ee4635312faf3
record_format Article
spelling doaj-ab726cf4de894ff0b40ee4635312faf32020-11-25T03:05:56ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062014-08-011REGULATORY T-CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIAGiovanni D'Arena0Giovanni Rossi1Barbara VannataSilvia DeaglioDepartment of Onco-Hematology, IRCCS “Centro di Riferimento Oncologico della Basilicata”, Via Padre Pio n. 1, 85028 Rionero in Vulture (Pz), Italy Phone: +39.0972.726521 FAX: +39.0972.726217),(2),(3),(4), Giovanna Mansueto (1), Fiorella D’Auria (5), Teodora Statuto (5), Vittorio Simeon (6), Laura De Martino (7), Aurelio Marandino (7), Giovanni Del Poeta (8), Vincenzo De Feo (7), Pellegrino Musto (1) Regulatory T-cells (Tregs) constitute a small subset of cells that are actively involved in maintaining self-tolerance, in immune homeostasis and in antitumor immunity. They are thought to play a significant role in the progression of cancer and are generally increased in patient with chronic lymphocytic leukemia (CLL). Their number correlates with more aggressive disease status and is predictive of the time to treatment, as well. Moreover, it is now clear that dysregulation in Tregs cell frequency and/or function may result in a plethora of autoimmune diseases, including multiple sclerosis, type 1 diabetes mellitus, myasthenia gravis, systemic lupus erythematosis, autoimmune lymphoproliferative disorders, rheumatoid arthritis, and psoriasis. Efforts are made aiming to develop approaches to deplete Tregs or inhibit their function in either cancer and autoimmune disorders. https://mjhid.org/index.php/mjhid/article/view/1680
collection DOAJ
language English
format Article
sources DOAJ
author Giovanni D'Arena
Giovanni Rossi
Barbara Vannata
Silvia Deaglio
spellingShingle Giovanni D'Arena
Giovanni Rossi
Barbara Vannata
Silvia Deaglio
REGULATORY T-CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA
Mediterranean Journal of Hematology and Infectious Diseases
author_facet Giovanni D'Arena
Giovanni Rossi
Barbara Vannata
Silvia Deaglio
author_sort Giovanni D'Arena
title REGULATORY T-CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA
title_short REGULATORY T-CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA
title_full REGULATORY T-CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA
title_fullStr REGULATORY T-CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA
title_full_unstemmed REGULATORY T-CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA
title_sort regulatory t-cells in chronic lymphocytic leukemia
publisher PAGEPress Publications
series Mediterranean Journal of Hematology and Infectious Diseases
issn 2035-3006
publishDate 2014-08-01
description Regulatory T-cells (Tregs) constitute a small subset of cells that are actively involved in maintaining self-tolerance, in immune homeostasis and in antitumor immunity. They are thought to play a significant role in the progression of cancer and are generally increased in patient with chronic lymphocytic leukemia (CLL). Their number correlates with more aggressive disease status and is predictive of the time to treatment, as well. Moreover, it is now clear that dysregulation in Tregs cell frequency and/or function may result in a plethora of autoimmune diseases, including multiple sclerosis, type 1 diabetes mellitus, myasthenia gravis, systemic lupus erythematosis, autoimmune lymphoproliferative disorders, rheumatoid arthritis, and psoriasis. Efforts are made aiming to develop approaches to deplete Tregs or inhibit their function in either cancer and autoimmune disorders.
url https://mjhid.org/index.php/mjhid/article/view/1680
work_keys_str_mv AT giovannidarena regulatorytcellsinchroniclymphocyticleukemia
AT giovannirossi regulatorytcellsinchroniclymphocyticleukemia
AT barbaravannata regulatorytcellsinchroniclymphocyticleukemia
AT silviadeaglio regulatorytcellsinchroniclymphocyticleukemia
_version_ 1724676323000975360